Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine
暂无分享,去创建一个
Cécile Viboud | Benjamin J Cowling | Martha I Nelson | David J Spiro | Suzanne L Epstein | Katelyn Gostic | Graeme E Price | Amanda Perofsky | Kaiyuan Sun | Nídia Sequeira Trovão | Katelyn M. Gostic | C. Viboud | B. Cowling | K. Sun | M. Nelson | D. Spiro | S. Epstein | Graeme E. Price | G. Price | K. Gostic | A. Perofsky | Nídia Sequeira Trovão
[1] J. Gog,et al. Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] Cécile Viboud,et al. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. , 2005, The Journal of infectious diseases.
[3] Jonathan J Deeks,et al. Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.
[4] James O. Lloyd-Smith,et al. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting , 2016, Science.
[5] T. Randall,et al. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.
[6] Mark A. Miller,et al. Influenza-Related Mortality Trends in Japanese and American Seniors: Evidence for the Indirect Mortality Benefits of Vaccinating Schoolchildren , 2011, PloS one.
[7] Michael B. Doud,et al. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin , 2018, Nature Communications.
[8] Caitlin E. Mullarkey,et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Mark A. Miller,et al. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control , 2007, Epidemiology and Infection.
[10] Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.
[11] Patrick C. Wilson,et al. Immune history profoundly affects broadly protective B cell responses to influenza , 2015, Science Translational Medicine.
[12] S. Hensley,et al. Immune history and influenza virus susceptibility. , 2017, Current opinion in virology.
[13] Kimihito Ito,et al. Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults , 2020, mBio.
[14] D. Nokes,et al. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach , 2017, Vaccine.
[15] Adolfo García-Sastre,et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.
[16] A. Monto,et al. Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States , 2018, The Journal of infectious diseases.
[17] P. Palese,et al. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.
[18] Jin Hyang Kim,et al. Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains. , 2016, Vaccine.
[19] P. Horby,et al. Influenza Infection Rates, Measurement Errors and the Interpretation of Paired Serology , 2012, PLoS pathogens.
[20] Mark A. Miller,et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.
[21] Anne M Johnson,et al. Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. , 2015, American journal of respiratory and critical care medicine.
[22] Matthew S. Miller,et al. Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic , 2018, mBio.
[23] Katelyn M. Gostic,et al. Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology. , 2017, Trends in microbiology.
[24] A. Read,et al. Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens , 2015, PLoS biology.
[25] David J. Topham,et al. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.
[26] C. M. Saad-Roy,et al. Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza , 2020, Journal of the Royal Society Interface.
[27] N. Arinaminpathy,et al. Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States , 2017, American journal of epidemiology.
[28] A. Flahault,et al. Estimating the impact of school closure on influenza transmission from Sentinel data , 2008, Nature.
[29] C. Viboud,et al. First flu is forever , 2016, Science.
[30] Esmeralda Alvarado-Facundo,et al. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it , 2019, PloS one.
[31] C. Viboud,et al. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data , 2004, Statistics in medicine.
[32] K. Subbarao,et al. Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus , 2014, Clinical and Vaccine Immunology.
[33] A S Perelson,et al. Variable efficacy of repeated annual influenza vaccination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Peiris,et al. Age-specific differences in the dynamics of protective immunity to influenza , 2018, Nature Communications.
[35] δ-Antigen , 2019, Springer Reference Medizin.
[36] Cecile Viboud,et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. , 2005, Archives of internal medicine.
[37] J. Schulman. EXPERIMENTAL TRANSMISSION OF INFLUENZA VIRUS INFECTION IN MICE , 1967, The Journal of experimental medicine.
[38] W. John Edmunds,et al. Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study , 2013, PLoS medicine.
[39] Stephen S Morse,et al. Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Diane J Post,et al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases , 2018, The Journal of infectious diseases.
[41] E. D. Kilbourne,et al. Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.
[42] Rong Hai,et al. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins , 2013, Proceedings of the National Academy of Sciences.
[43] L. Simonsen,et al. The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.
[44] C. A. Russell,et al. Antibody landscapes after influenza virus infection or vaccination , 2014, Science.
[45] J. A. Misplon,et al. Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen. , 2018, Vaccine.
[46] B. Cowling,et al. Sample Size Considerations for One-to-One Animal Transmission Studies of the Influenza A Viruses , 2013, PloS one.
[47] P. Horby,et al. Determinants of Influenza Transmission in South East Asia: Insights from a Household Cohort Study in Vietnam , 2014, PLoS pathogens.
[48] J. Bloom,et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season , 2014, Proceedings of the National Academy of Sciences.
[49] Cecile Viboud,et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza , 2012, Proceedings of the National Academy of Sciences.
[50] A. Sant,et al. Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus , 2019, Front. Immunol..
[51] L. Simonsen,et al. The virtues of antigenic sin: consequences of pandemic recycling on influenza-associated mortality , 2004 .
[52] Benjamin J Cowling,et al. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] J. A. Misplon,et al. Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model , 2014, Journal of Virology.
[54] Francisco A. Chaves,et al. Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus , 2019, Journal of Virology.
[55] Mark A. Miller,et al. Transmission potential of influenza A/H7N9, February to May 2013, China , 2013, BMC Medicine.
[56] Tao Dong,et al. Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] Christopher S. Anderson,et al. Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain , 2017, Scientific Reports.
[58] Xiyan Xu,et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.
[59] Gavin J. D. Smith,et al. Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China , 2012, PLoS pathogens.
[60] Libo Dong,et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.
[61] F. Krammer. Novel universal influenza virus vaccine approaches. , 2016, Current opinion in virology.
[62] Christopher T. Stamper,et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial , 2019, The Lancet. Infectious diseases.
[63] A. Hill,et al. Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[64] Cécile Viboud,et al. Searching for Sharp Drops in the Incidence of Pandemic A/H1N1 Influenza by Single Year of Age , 2012, PloS one.
[65] A. Monto,et al. Stochastic processes constrain the within and between host evolution of influenza virus , 2018, eLife.
[66] D. Suarez,et al. Influenza neuraminidase as a vaccine antigen. , 2009, Current topics in microbiology and immunology.
[67] Mark M. Davis,et al. Lineage Structure of the Human Antibody Repertoire in Response to Influenza Vaccination , 2013, Science Translational Medicine.
[68] R. Lamb,et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice , 1990, Journal of virology.
[69] Nimalan Arinaminpathy,et al. Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines , 2016, PLoS Comput. Biol..
[70] Katelyn M. Gostic,et al. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics , 2019, PLoS pathogens.
[71] Strains , 2020, Encyclopedia of Continuum Mechanics.
[72] D. Cummings,et al. Timescales of influenza A/H3N2 antibody dynamics , 2017, bioRxiv.
[73] A. Read,et al. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance , 2018, Proceedings of the National Academy of Sciences.
[74] Benjamin J Cowling,et al. Comparative epidemiology of pandemic and seasonal influenza A in households. , 2010, The New England journal of medicine.
[75] L. Brammer,et al. Birth Cohort Effects in Influenza Surveillance Data: Evidence that First Influenza Infection Affects Later Influenza-Associated Illness. , 2019, The Journal of infectious diseases.
[76] A. Monto,et al. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. , 1970, The Journal of infectious diseases.
[77] W. Barclay,et al. Transmission of a 2009 H1N1 Pandemic Influenza Virus Occurs before Fever Is Detected, in the Ferret Model , 2012, PloS one.
[78] Trevor Bedford,et al. Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants , 2018, Proceedings of the National Academy of Sciences.
[79] P. Wilson,et al. The influenza virus hemagglutinin head evolves faster than the stalk domain , 2018, Scientific Reports.
[80] P. Collins,et al. Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.
[81] Mark A. Miller,et al. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses , 2009, Virology.
[82] T. Ben-Yedidia,et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. , 2014, Vaccine.
[83] D. Earn,et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. , 2010, JAMA.
[84] Ross Upshur,et al. The Effect of Universal Influenza Immunization on Mortality and Health Care Use , 2008, PLoS medicine.
[85] S. Epstein. Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo. , 2018, American journal of epidemiology.
[86] J. Peiris,et al. Influenza A Virus Shedding and Infectivity in Households. , 2015, The Journal of infectious diseases.
[87] R. Albrecht,et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies , 2017, npj Vaccines.
[88] Michael G. Buhnerkempe,et al. Mapping influenza transmission in the ferret model to transmission in humans , 2015, eLife.
[89] J. Mascola,et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.
[90] W. C. Hwang,et al. Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[91] M. Eichelberger,et al. Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin , 2017, mBio.
[92] R. Glover,et al. Spread of Infection from the Respiratory Tract of the Ferret. I. Transmission of Influenza A Virus. , 1941 .
[93] A. Kelso,et al. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity , 2015, mBio.
[94] P. Wilson,et al. Harnessing immune history to combat influenza viruses. , 2018, Current opinion in immunology.
[95] James E. Crowe,et al. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.
[96] R. Varadarajan,et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem , 2016, Scientific Reports.
[97] Raul Rabadan,et al. Differences in Patient Age Distribution between Influenza A Subtypes , 2009, PloS one.
[98] Thomas Francis,et al. EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.
[99] N. Cox,et al. Global epidemiology of influenza: past and present. , 2000, Annual review of medicine.
[100] C. M. Saad-Roy,et al. Dynamic Perspectives on the Search for a Universal Influenza Vaccine. , 2019, The Journal of infectious diseases.
[101] David Baltimore,et al. Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.
[102] A. Monto,et al. The Doctrine of Original Antigenic Sin: Separating Good From Evil , 2017, The Journal of infectious diseases.
[103] Rahul Raman,et al. Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift , 2009, Science.
[104] S. de Lusignan,et al. Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[105] Walter Fiers,et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.
[106] E. Belongia,et al. Earliest infections predict the age distribution of seasonal influenza A cases , 2019, eLife.
[107] J. Bloom,et al. Parallel evolution of influenza across multiple spatiotemporal scales , 2017, eLife.
[108] N. Ferguson,et al. Ecological and immunological determinants of influenza evolution , 2003, Nature.
[109] S. Epstein. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. , 2006, The Journal of infectious diseases.
[110] A. Osterhaus,et al. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. , 2006, Vaccine.
[111] Karlynn E. Neu,et al. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study , 2019, Journal of Virology.